Clinical trialPhase 2Completed
Open-label Study of CS-1008 for Subjects With Untreated and Unresectable Pancreatic Cancer
Phase 2 Multicenter, Open-Label Study of CS-1008, A Humanized Monoclonal Antibody Targeting Death Receptor 5 (DR5), In Combination With Gemcitabine in Chemotherapy Naive Subjects With Unresectable or Metastatic Pancreatic Cancer
- Outcome
- Results posted; single-arm, no comparison
- Phase
- Phase 2
- Status
- Completed
- Study type
- Interventional
- Start
- 15 August 2007
- Ended
- 20 August 2010
- Enrollment
- 65 participants
- Sites
- 12
- Primary outcomes
- Progression-Free Survival Rate at 16 Weeks Following Treatment With CS-1008 in Combination With Gemcitabine in Chemotherapy-Naïve Participants With Unresectable or Metastatic Pancreatic Cancer
- Sponsor type
- Industry
- Results posted
- 3 December 2020
- Last update
- 8 April 2021
These fields come from the trial’s registry entry. A summary of its population, design, endpoints and results, each tied to a quote, has not been written for this trial yet.
Results
- Primary endpoint
- Results posted; single-arm, no comparisonAs posted on ClinicalTrials.gov ↗, registry record of 8 April 2021
- PFS
- Progression-Free Survival Rate at 16 Weeks Following Treatment With CS-1008 in Combination With Gemcitabine in Chemotherapy-Naïve Participants With Unresectable or Metastatic Pancreatic CancerCS-1008 + Gemcitabine: 52.5 (39.3 to 64.1), n = 61Values: Percentage of participants, 95% Confidence IntervalTime frame: Baseline to the date of disease progression or death due to any cause (whichever occurs first), up to 16 weeks post dose.No analysis posted for this outcome (outcome 1)
- Participants
- CS-1008 + Gemcitabine: 62 started, 0 completed
- Serious adverse events
- CS-1008 + Gemcitabine: 35 of 62Participants with at least one serious adverse event, of those at risk, as posted
5 secondary outcomes
- PFS · Kaplan-Meier (Non-Parametric) Analysis of Progression-Free Survival Following Treat…
- PFS Rate at 3 Months (%): CS-1008 + Gemcitabine 59.0 (45.7 to 70.1), n=61 [Percentage of participants, 95% Confidence Interval] (first of 4 rows)
- OS · Overall Survival Following Treatment With CS-1008 in Combination With Gemcitabine in…
- OS Rate at 6 Months (%): CS-1008 + Gemcitabine 55.7 (42.4 to 67.1), n=61 [Percentage of participants, 95% Confidence Interval] (first of 4 rows)
- Best Overall Tumor Response Following Treatment With CS-1008 in Combination With Gemcitab…
- Confirmed CR: CS-1008 + Gemcitabine 0/61 [Participants] (first of 8 rows)
- Number of Participants With Treatment-Emergent Adverse Events Considered by the Investiga…
- Any TEAE: CS-1008 + Gemcitabine 43/62 [Participants] (first of 21 rows)
- Number of Participants With Treatment-Emergent Adverse Events Considered by the Investiga…
- Any TEAE: CS-1008 + Gemcitabine 54/62 [Participants] (first of 27 rows)
Every value is copied from the trial’s results record at ClinicalTrials.gov. “Statistically significant” describes the posted test only: it does not say which group did better, and nothing here is read from a paper.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess.
Try
Source text
Brief summary public domain (ClinicalTrials.gov)
Phase 2 study to determine the efficacy and safety of CS-1008 when given with gemcitabine to subjects with previously untreated and unresectable (unable to be surgically removed) or metastatic (spread to other areas beyond the pancreas) pancreatic cancer.
Detailed description public domain (ClinicalTrials.gov)
Primary Objective: \- To evaluate the efficacy of CS-1008 administered in combination with gemcitabine to chemotherapy naive subjects with unresectable or metastatic pancreatic cancer, based on the progression-free survival at 16 weeks. Secondary Objectives: * To evaluate the efficacy of CS-1008 administered in combination with gemcitabine on overall progression-free survival rate, objective response rate, duration of response, and overall survival. * To determine the pharmacokinetics of BIP CS-1008 and DSC CS-1008. * To study potential biomarkers of CS-1008 activity * To assess possible human anti-human antibody formation after exposure to CS-1008 * To evaluate the safety profile of CS-1008 when administered in combination with gemcitabine to chemotherapy naive subjects with unresectable or metastatic pancreatic cancer.
Posted results (ClinicalTrials.gov registry) · primary outcome public domain (ClinicalTrials.gov)
Progression-Free Survival Rate at 16 Weeks Following Treatment With CS-1008 in Combination With Gemcitabine in Chemotherapy-Naïve Participants With Unresectable or Metastatic Pancreatic Cancer [Baseline to the date of disease progression or death due to any cause (whichever occurs first), up to 16 weeks post dose.]. Number, Percentage of participants (95% Confidence Interval). CS-1008 + Gemcitabine (n=61): 52.5 (39.3 to 64.1).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Kaplan-Meier (Non-Parametric) Analysis of Progression-Free Survival Following Treatment With CS-1008 in Combination With Gemcitabine in Chemotherapy-Naïve Participants With Unresectable or Metastatic Pancreatic Cancer [Baseline up to date of disease progression or death due to any cause (whichever occurs first), up to approximately 36 months post dose.]. Number, Percentage of participants (95% Confidence Interval). PFS Rate at 3 Months (%): CS-1008 + Gemcitabine (n=61): 59.0 (45.7 to 70.1). PFS Rate at 6 Months (%): CS-1008 + Gemcitabine (n=61): 34.4 (22.9 to 46.3). PFS Rate at 9 Months (%): CS-1008 + Gemcitabine (n=61): 21.3 (12.1 to 32.2). PFS Rate at 1 Year (%): CS-1008 + Gemcitabine (n=61): 13.1 (6.1 to 22.8).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Overall Survival Following Treatment With CS-1008 in Combination With Gemcitabine in Chemotherapy-Naïve Participants With Unresectable or Metastatic Pancreatic Cancer [Baseline to death due to any cause, up to approximately 36 months post dose.]. Number, Percentage of participants (95% Confidence Interval). OS Rate at 6 Months (%): CS-1008 + Gemcitabine (n=61): 55.7 (42.4 to 67.1). OS Rate at 9 Months (%): CS-1008 + Gemcitabine (n=61): 41.0 (28.6 to 52.9). OS Rate at 1 Year (%): CS-1008 + Gemcitabine (n=61): 24.6 (14.7 to 35.9). OS Rate at 15 Months (%): CS-1008 + Gemcitabine (n=61): 13.1 (6.1 to 22.8).
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Best Overall Tumor Response Following Treatment With CS-1008 in Combination With Gemcitabine in Chemotherapy-Naïve Participants With Unresectable or Metastatic Pancreatic Cancer [Baseline to up to date of first documented objective response or disease progression (whichever occurs first), up to approximately 36 months post dose.]. Count Of Participants, Participants. Confirmed CR: CS-1008 + Gemcitabine (n=61): 0. Confirmed PR: CS-1008 + Gemcitabine (n=61): 5. Objective Response (confirmed CR or PR): CS-1008 + Gemcitabine (n=61): 5. Unconfirmed CR: CS-1008 + Gemcitabine (n=61): 0. Unconfirmed PR: CS-1008 + Gemcitabine (n=61): 3. Stable Disease (SD): CS-1008 + Gemcitabine (n=61): 28. Progressive Disease (PD): CS-1008 + Gemcitabine (n=61): 14. Unknown: CS-1008 + Gemcitabine (n=61): 11.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Number of Participants With Treatment-Emergent Adverse Events Considered by the Investigator at Least Possibly Related to CS-1008 Experienced by ≥5% of Participants by System Organ Class and Preferred Term [Baseline up to 30 days post last dose, up to approximately 36 months post dose.]. Count Of Participants, Participants. Any TEAE: CS-1008 + Gemcitabine (n=62): 43. Anemia: CS-1008 + Gemcitabine (n=62): 8. Neutropenia: CS-1008 + Gemcitabine (n=62): 4. Thrombocytopenia: CS-1008 + Gemcitabine (n=62): 5. Abdominal Pain: CS-1008 + Gemcitabine (n=62): 5. Constipation: CS-1008 + Gemcitabine (n=62): 8. Diarrhea: CS-1008 + Gemcitabine (n=62): 8. Nausea: CS-1008 + Gemcitabine (n=62): 22. Vomiting: CS-1008 + Gemcitabine (n=62): 8. Asthenia: CS-1008 + Gemcitabine (n=62): 11. Fatigue: CS-1008 + Gemcitabine (n=62): 20. Oedma peripheral: CS-1008 + Gemcitabine (n=62): 12. Pyrexia: CS-1008 + Gemcitabine (n=62): 10. Haemoglobin decreased: CS-1008 + Gemcitabine (n=62): 6. Neutrophil count decreased: CS-1008 + Gemcitabine (n=62): 5. White blood cell count decreased: CS-1008 + Gemcitabine (n=62): 4. Anorexia: CS-1008 + Gemcitabine (n=62): 8. Dysgeusia: CS-1008 + Gemcitabine (n=62): 4. Headache: CS-1008 + Gemcitabine (n=62): 6. Rash: CS-1008 + Gemcitabine (n=62): 4. Hypertension: CS-1008 + Gemcitabine (n=62): 4.
Posted results (ClinicalTrials.gov registry) · secondary outcome public domain (ClinicalTrials.gov)
Number of Participants With Treatment-Emergent Adverse Events Considered by the Investigator at Least Possibly Related to Gemcitabine Experienced by ≥5% of Participants by System Organ Class and Preferred Term [Baseline up to 30 days post last dose, up to approximately 36 months post dose.]. Count Of Participants, Participants. Any TEAE: CS-1008 + Gemcitabine (n=62): 54. Anemia: CS-1008 + Gemcitabine (n=62): 15. Leukopenia: CS-1008 + Gemcitabine (n=62): 4. Lymphopena: CS-1008 + Gemcitabine (n=62): 5. Thrombocytopenia: CS-1008 + Gemcitabine (n=62): 11. Abdominal distension: CS-1008 + Gemcitabine (n=62): 4. Abdominal pain: CS-1008 + Gemcitabine (n=62): 5. Constipation: CS-1008 + Gemcitabine (n=62): 7. Diarrhea: CS-1008 + Gemcitabine (n=62): 11. Nausea: CS-1008 + Gemcitabine (n=62): 31. Vomiting: CS-1008 + Gemcitabine (n=62): 20. Asthenia: CS-1008 + Gemcitabine (n=62): 12. Chills: CS-1008 + Gemcitabine (n=62): 5. Fatigue: CS-1008 + Gemcitabine (n=62): 22. Oedema peripheral: CS-1008 + Gemcitabine (n=62): 10. Pyrexia: CS-1008 + Gemcitabine (n=62): 11. Haemoglobin decreased: CS-1008 + Gemcitabine (n=62): 10. Neutrophil count decreased: CS-1008 + Gemcitabine (n=62): 9. Platelet count decreased: CS-1008 + Gemcitabine (n=62): 9. White blood cell count decreased: CS-1008 + Gemcitabine (n=62): 7. Anorexia: CS-1008 + Gemcitabine (n=62): 8. Dehydration: CS-1008 + Gemcitabine (n=62): 5. Dysgeusia: CS-1008 + Gemcitabine (n=62): 4. Headache: CS-1008 + Gemcitabine (n=62): 6. Alopecia: CS-1008 + Gemcitabine (n=62): 4. Night Sweats: CS-1008 + Gemcitabine (n=62): 4. Rash: CS-1008 + Gemcitabine (n=62): 5.